Stockscreener 앱 받기
55.00
1.72%
-0.96
시간 외 거래:
55.49
0.49
+0.89%
전일 마감가:
$55.96
열려 있는:
$56.23
하루 거래량:
1.60M
Relative Volume:
0.52
시가총액:
$4.75B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-19.64
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
-1.94%
1개월 성능:
+0.33%
6개월 성능:
+38.50%
1년 성능:
+14.92%
1일 변동 폭
$54.39
$56.37
1주일 범위
$52.50
$59.89
52주 변동 폭
$30.04
$71.13
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
55.00 | 5.12B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Westwood Holdings Group Inc. - MarketBeat
Cantor Fitzgerald Has Weak Estimate for CRSP FY2025 Earnings - MarketBeat
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
Blair William & Co. IL Has $2.32 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Cetera Investment Advisers Has $1.97 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Barclays Issues Positive Forecast for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price - MarketBeat
CRISPR Therapeutics AG Insider Buying: Douglas Treco Acquires 20,000 Shares - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Given "Buy" Rating at Chardan Capital - MarketBeat
Crispr Therapeutics Faces Stock Dip Amid Promising Developments - TipRanks
Crispr Therapeutics AG (CRSP) Gets a Buy from Truist Financial - The Globe and Mail
Royal Bank Of Canada Increases CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $42.00 - MarketBeat
Director Makes Bold Move with Major Stock Purchase in Crispr Therapeutics AG! - TipRanks
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - MSN
Crispr Therapeutics price target raised to $12 from $10 at Barclays - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Posts Quarterly Earnings Results - MarketBeat
CRSP Stock Analysis: What’s Going on with Crispr Therapeutics AG? - Markets.com
Brookline Capital Management Estimates CRSP Q3 Earnings - MarketBeat
Leerink Partnrs Has Pessimistic View of CRSP Q3 Earnings - MarketBeat
Crispr Therapeutics AG: Strong Sales Growth and Global Expansion Justify Buy Rating - TipRanks
Research Analysts Set Expectations for CRSP FY2027 Earnings - MarketBeat
CRISPR Therapeutics stock price target raised to $80 by H.C. Wainwright - Investing.com Nigeria
Banque Cantonale Vaudoise Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Privium Fund Management B.V. Acquires 25,100 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Earnings: Casgevy Launch Gains Momentum; Early-Stage Pipeline Progresses; Shares Undervalued - Morningstar
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption - MSN
CRISPR Therapeutics Shares Drop 6.71% on Q2 Losses and $96M Charge as $250M Volume Ranks 475th - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap DownShould You Sell? - MarketBeat
Up 50% in 3 Months, Is This Stock Still a Buy? - The Motley Fool
Crispr Therapeutics AG: Strong Financial Foundation and Promising Pipeline Amidst Strategic Growth - TipRanks
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics Plunges 9.63% Ahead of Q2 Earnings - AInvest
Crispr Therapeutics AG: Promising Growth and Expanding Pipeline Justify Buy Rating - TipRanks
Bayforest Capital Ltd Purchases Shares of 12,424 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - MSN
CRISPR Therapeutics AG reports results for the quarter ended June 30Earnings Summary - TradingView
Crispr Therapeutics shares tumble after significant earnings miss By Investing.com - Investing.com Nigeria
Crispr Therapeutics shares tumble after significant earnings miss - Investing.com
Crispr Therapeutics earnings missed by $1.00, revenue fell short of estimates - Investing.com
CRISPR Therapeutics AG SEC 10-Q Report - TradingView
CRISPR Therapeutics Q2 revenue misses estimates, net loss widens - MarketScreener
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Published on: 2025-08-04 01:34:11 - Jammu Links News
What analysts say about CRISPR Therapeutics AG stockCapitalize on market trends with confidence - Jammu Links News
What are CRISPR Therapeutics AG company’s key revenue driversCapitalize on fast-moving stock trends - Jammu Links News
What are the latest earnings results for CRISPR Therapeutics AGMaximize gains with data-driven stock picks - Jammu Links News
What is Zacks Research's Estimate for CRSP Q2 Earnings? - MarketBeat
When is CRISPR Therapeutics AG stock expected to show significant growthFree Trading Strategy Suggestions - Jammu Links News
What drives CRISPR Therapeutics AG stock priceAchieve consistent double-digit growth - Jammu Links News
Published on: 2025-08-03 05:26:58 - Jammu Links News
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):